User's Manual

US-ENGLISH – 63
The graph shows that many patients programmed to SafeR had less than
1% ventricular pacing:
 84 % of patients without AV block at implant.
 63 % of patients with AV block at implant.
In a representative reference group
1
(1)
of patients programmed to DDD,
none had less than 1 % ventricular pacing and only 10 % had less than
90 % ventricular pacing regardless of AV block indication at implant.
The actual reduction of ventricular pacing that SafeR provides in an
individual will depend on the amount of time that the patient spends in AV
block. SafeR cannot and should not provide any decrease in ventricular
pacing while the patient is in AV block.
(1) Pioger G, Jauvert G, Nitzsché R, Pozzan J, Laure H, Zigelman M, Leny G,
Vandrell M, Ritter P, and Cazeau S. Incidence and predictive factors of atrial
fibrillation in paced patients. PACE, 28, Supp 1: S137-141; January 2005. This
was a prospective observational study of 377 patients with a functionally similar
device programmed to DDD. The primary indications for implant were: AV block
(49 %), sinus node disease (16 %), brady-tachy syndrome (5 %), AV block +
sinus node disease (19 %), AV block + brady-tachy syndrome (6 %), and brady-
tachy syndrome + sinus node disease (5 %).